keyword
MENU ▼
Read by QxMD icon Read
search

oral palonosetron

keyword
https://www.readbyqxmd.com/read/27889278/safety-and-efficacy-of-nepa-an-oral-fixed-combination-of-netupitant-and-palonosetron-in-older-patients
#1
Matti Aapro, Karin Jordan, Richard J Gralla, Giada Rizzi, Giorgia Rossi, Marco Palmas, Anna V Alyasova, Alla S Lisyanskaya, Snežana M Bošnjak, Paul J Hesketh
OBJECTIVES: Prevention of chemotherapy-induced nausea and vomiting is critical in older cancer patients. NEPA is an oral fixed combination of netupitant 300mg, a new NK1 receptor antagonist (RA), and palonosetron 0.5mg, a pharmacologically distinct 5-HT3 RA. This retrospective analysis evaluated the efficacy and safety of NEPA in older patients. METHODS: Patients aged ≥65 and ≥70years from one phase II and two phase III trials were considered. Chemotherapy-naive patients with malignant tumors were treated with anthracycline-cyclophosphamide (AC), non-AC-based moderately emetogenic chemotherapy (non-AC MEC), or highly emetogenic chemotherapy (HEC)...
November 23, 2016: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/27885469/nepa-a-fixed-oral-combination-of-netupitant-and-palonosetron-improves-control-of-chemotherapy-induced-nausea-and-vomiting-cinv-over-multiple-cycles-of-chemotherapy-results-of-a-randomized-double-blind-phase-3-trial-versus-oral-palonosetron
#2
Matti Aapro, Meinolf Karthaus, Lee Schwartzberg, Igor Bondarenko, Tomasz Sarosiek, Cristina Oprean, Servando Cardona-Huerta, Vincent Hansen, Giorgia Rossi, Giada Rizzi, Maria Elisa Borroni, Hope Rugo
PURPOSE: Antiemetic guidelines recommend co-administration of targeted prophylactic medications inhibiting molecular pathways involved in emesis. NEPA is a fixed oral combination of a new NK1 receptor antagonist (RA), netupitant (NETU 300 mg), and palonosetron (PALO 0.50 mg), a pharmacologically distinct 5-HT3 RA. NEPA showed superior prevention of chemotherapy-induced nausea and vomiting (CINV) compared with oral PALO in a single chemotherapy cycle; maintenance of efficacy/safety over continuing cycles is the objective of this study...
November 24, 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27873176/palonosetron-aprepitant-and-dexamethasone-for-prevention-of-nausea-and-vomiting-after-high-dose-melphalan-in-autologous-transplantation-for-multiple-myeloma-a-phase-ii-study
#3
Atsushi Isoda, Rie Saito, Fuminori Komatsu, Yuki Negishi, Noriyasu Oosawa, Tetsuya Ishikawa, Yuri Miyazawa, Morio Matsumoto, Morio Sawamura, Akihiro Manaka
Chemotherapy-induced nausea and vomiting (CINV) is a significant side effect in multiple myeloma (MM) patients receiving high-dose melphalan treatment followed by autologous stem cell transplantation (ASCT). We evaluated the efficacy and safety of a triple antiemetic combination of palonosetron, aprepitant, and low-dose dexamethasone in 24 MM patients who received melphalan conditioning (100 mg/m(2) on days 1-2) before ASCT (on day 4). Intravenous palonosetron (0.75 mg on day 1), oral aprepitant (125 mg on day 1; 80 mg on days 2-4), and intravenous dexamethasone (6...
November 21, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27713845/the-first-oral-fixed-dose-combination-of-netupitant-and-palonosetron-for-the-treatment-of-chemotherapy-induced-nausea-and-vomiting
#4
Joseph W Coyne
No abstract text is available yet for this article.
January 2016: Journal of the Advanced Practitioner in Oncology
https://www.readbyqxmd.com/read/27612464/a-prospective-study-of-the-antiemetic-effect-of-palonosetron-in-malignant-lymphoma-patients-treated-with-the-chop-regimen
#5
Yoshiharu Miyata, Kimikazu Yakushijin, Yumiko Inui, Yoshinori Imamura, Hideaki Goto, Yu Mizutani, Keiji Kurata, Seiji Kakiuchi, Yukinari Sanada, Yosuke Minami, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Ryo Tominaga, Hiroshi Gomyo, Ishikazu Mizuno, Tetsuhiko Nomura, Koichi Kitagawa, Takeshi Sugimoto, Tohru Murayama, Hiroshi Matsuoka, Hironobu Minami
To identify strategies for reducing emesis induced by the CHOP regimen, which includes high-dose steroids, we prospectively evaluated the efficacy of palonosetron in Japanese patients. Palonosetron was administered at a dose of 0.75 mg via intravenous injection over 30 min before chemotherapy on day 1. Patients kept diaries of chemotherapy-induced nausea and vomiting (CINV) incidence from the start of chemotherapy until 168 h afterwards, in which they documented the occurrence and severity of nausea, vomiting, anorexia, and the use of rescue medication...
September 9, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27473611/ca-2-signaling-and-emesis-recent-progress-and-new-perspectives
#6
Weixia Zhong, Andrew J Picca, Albert S Lee, Nissar A Darmani
Cisplatin-like chemotherapeutics cause vomiting via calcium (Ca(2+))-dependent release of multiple neurotransmitters (dopamine, serotonin, substance P, etc.) from the gastrointestinal enterochromaffin cells and/or the brainstem. Intracellular Ca(2+) signaling is triggered by activation of diverse emetic receptors (including tachykininergic NK1, serotonergic 5-HT3, dopaminergic D2, cholinergic M1, or histaminergic H1), whose activation in vomit-competent species can evoke emesis. Other emetogens such as cisplatin, rotavirus NSP4 protein and bacterial toxins can also induce intracellular Ca(2+) elevation...
July 26, 2016: Autonomic Neuroscience: Basic & Clinical
https://www.readbyqxmd.com/read/27354807/management-of-chemotherapy-induced-nausea-and-vomiting-by-risk-profile-role-of-netupitant-palonosetron
#7
REVIEW
Vito Lorusso
As recommended by most recent antiemetic guidelines, the optimal prophylaxis of chemotherapy-induced nausea and vomiting (CINV) requires the combination of 5-HT3 receptor antagonist (RA) with an NK1-RA. Moreover, the major predictors of acute and delayed CINV include: young age, female sex, platinum- or anthracycline-based chemotherapy, nondrinker status, emesis in the earlier cycles of chemotherapy, and previous history of motion/morning sickness. Despite improved knowledge of the pathophysiology of CINV and advances in the availability of active antiemetics, an inconsistent compliance with their use has been reported, thereby resulting in suboptimal control of CINV in several cases...
2016: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/27286875/efficacy-of-palonosetron-plus-aprepitant-in-preventing-chemoradiotherapy-induced-nausea-and-emesis-in-patients-receiving-daily-low-dose-cisplatin-based-concurrent-chemoradiotherapy-for-uterine-cervical-cancer-a-phase-ii-study
#8
Shinsuke Hanawa, Akira Mitsuhashi, Ayumu Matsuoka, Kyoko Nishikimi, Shinichi Tate, Hirokazu Usui, Takashi Uno, Makio Shozu
PURPOSE: Antiemetic recommendations during concurrent chemoradiotherapy (cisplatin-based concurrent chemoradiotherapy (CCRT)) have not been established yet. The aim of this study was to investigate whether the combination of palonosetron plus aprepitant, without routine use of dexamethasone, could alleviate chemoradiotherapy-induced nausea and vomiting (CRINV). METHODS: This was a non-randomized, prospective, single-center, open phase II study. Patients with cervical cancer, who were treated with daily low-dose cisplatin (8 mg/m(2)/day) and concurrent radiation (2 Gy/day, 25 fractions, five times a week), were enrolled in this study...
November 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27254283/aprepitant-granisetron-and-dexamethasone-versus-palonosetron-and-dexamethasone-for-prophylaxis-of-cisplatin-induced-nausea-and-vomiting-in-patients-with-upper-gastrointestinal-cancer-a-randomized-crossover-phase-ii-trial-kdog-1002
#9
Kenji Ishido, Katsuhiko Higuchi, Mizutomo Azuma, Tohru Sasaki, Satoshi Tanabe, Chikatoshi Katada, Takafumi Yano, Takuya Wada, Wasaburo Koizumi
We conducted a randomized trial to compare the safety and effectiveness of aprepitant, granisetron, and dexamethasone (AGD) with those of palonosetron and dexamethasone (PD) in patients who received highly emetogenic chemotherapy (HEC). Patients with esophageal or gastric cancer who were scheduled to receive HEC including at least 60 mg/m of cisplatin as the first-line treatment were randomly assigned to receive AGD (oral aprepitant 125 mg on day 1 and 80 mg on days 2-3; intravenous granisetron 3 mg on day 1; intravenous dexamethasone 6...
October 2016: Anti-cancer Drugs
https://www.readbyqxmd.com/read/27194913/management-of-acute-and-delayed-chemotherapy-induced-nausea-and-vomiting-role-of-netupitant-palonosetron-combination
#10
REVIEW
Piotr K Janicki
PURPOSE: The purpose of this review is to summarize and discuss the recently published data (both original studies and reviews) on the oral medication NEPA, consisting of netupitant (a neurokinin-1 receptor antagonist [NK1RA], 300 mg dose) and palonosetron (5-hydroxytryptamine [serotonin or 5HT] type 3 receptor antagonist [5HT3RA], 0.5 mg dose), in the prevention of the acute and delayed nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy. METHODS: This review was based on the very limited number of available published trials consisting of two Phase III studies and one Phase II dose-selecting trial...
2016: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/27184113/management-of-chemotherapy-induced-nausea-and-vomiting-in-patients-receiving-multiple-day-highly-or-moderately-emetogenic-chemotherapy-role-of-transdermal-granisetron
#11
Flaminia Coluzzi, Consalvo Mattia
Granisetron transdermal delivery system (GTDS) is the first 5-HT3 drug to be transdermally delivered and represents a convenient alternative to oral and intravenous antiemetics for the treatment of chemotherapy-induced nausea and vomiting. GTDS is effective and well tolerated in patients receiving multiple-day moderate-to-highly emetogenic chemotherapy. In this setting noninferiority studies showed similar efficacy when GTDS was compared with intravenous and oral granisetron and intravenous palonosetron. GTDS has shown good cardiovascular safety; however, special caution is needed in patients at risk for developing excessive QTc interval prolongation and arrhythmias...
August 2016: Future Oncology
https://www.readbyqxmd.com/read/27152512/olanzapine-versus-fosaprepitant-for-the-prevention-of-concurrent-chemotherapy-radiotherapy-induced-nausea-and-vomiting
#12
Rudolph M Navari, Cindy K Nagy, Jennifer Le-Rademacher, Charles L Loprinzi
BACKGROUND: Concurrent chemotherapy radiation therapy may result in significant nausea and vomiting. There have been few studies reporting effective interventions for preventing treatment-related nausea and vomiting. OBJECTIVE: To compare olanzapine with fosaprepitant for the prevention of nausea and vomiting in patients receiving concurrent highly emetogenic chemotherapy (HEC) and radiotherapy for locally advanced head and neck or esophageal cancer. METHODS: 120 chemotherapy and radiotherapy naïve patients with head and neck cancer who were receiving concurrent local radiation and cisplatin were randomized to receive either olanzapine or fosaprepitant in combination with palonosetron and dexamethasone for the prevention of chemotherapy- and radiation-induced nausea and vomiting...
April 2016: Journal of Community and Supportive Oncology
https://www.readbyqxmd.com/read/27137147/evaluation-of-the-effect-of-food-and-age-on-the-pharmacokinetics-of-oral-netupitant-and-palonosetron-in-healthy-subjects-a-randomized-open-label-crossover-phase-1-study
#13
Selma Calcagnile, Corinna Lanzarotti, Michaela Gutacker, Verena Jakob-Rodamer, Klaus Peter Kammerer, Wolfgang Timmer
Antiemetic treatment compliance is important to prevent chemotherapy-induced nausea and vomiting, a feared chemotherapy side effect. NEPA, a new oral fixed combination of netupitant, a highly selective NK1 receptor antagonist (RA), and palonosetron, a second-generation 5-HT3 RA, targets dual antiemetic pathways with a single dose. This study investigated the effect of food intake and age on NEPA pharmacokinetics (PK) and safety. In this open-label, single-center, randomized, phase 1 study, 24 adults (18-45 years) received NEPA in a fed or fasted state during the first treatment period and in the alternative state in the next treatment period...
September 2015: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/27105599/combination-of-palonosetron-aprepitant-and-dexamethasone-as-primary-antiemetic-prophylaxis-for-cisplatin-based-chemotherapy
#14
Chan-Keng Yang, Chiao-En Wu, Chuang-Chi Liaw
BACKGROUND: The purpose of this study was to evaluate the efficacy of combined treatment with the long-acting 5-hydroxytryptamine receptor-3 antagonist, palonosetron, the neurokinin-1 receptor antagonist, oral aprepitant, and dexamethasone as primary antiemetic prophylaxis for cancer patients receiving highly emetogenic cisplatin-based chemotherapy. METHODS: Chemotherapy-naïve patients received the triple combination of palonosetron (0.25 mg), aprepitant (125 mg on day 1 and 80 mg on days 2 and 3), and dexamethasone (20 mg) from the beginning of highly emetogenic chemotherapy with cisplatin-based (≥50 mg/m(2)) regimens...
February 2016: Biomedical Journal
https://www.readbyqxmd.com/read/27000465/safety-of-an-oral-fixed-combination-of-netupitant-and-palonosetron-nepa-pooled-data-from-the-phase-ii-iii-clinical-program
#15
Matti Aapro, Paul J Hesketh, Karin Jordan, Richard J Gralla, Giorgia Rossi, Giada Rizzi, Marco Palmas
BACKGROUND: Standard prophylaxis for chemotherapy-induced nausea and vomiting (CINV) with highly emetogenic and anthracycline-cyclophosphamide-based chemotherapy includes a 5-hydroxytryptamine-3 receptor antagonist, a neurokinin-1 receptor antagonist (NK1RA), and corticosteroid therapy. NEPA is a fixed combination of netupitant and palonosetron. The primary objective of this analysis was to document the safety profile, including cardiac safety, of NEPA + dexamethasone in comparison with current therapies across all phase II/III trials...
April 2016: Oncologist
https://www.readbyqxmd.com/read/26952945/efficacy-and-safety-of-fosaprepitant-for-the-prevention-of-nausea-and-emesis-during-5-weeks-of-chemoradiotherapy-for-cervical-cancer-the-gand-emesis-study-a-multinational-randomised-placebo-controlled-double-blind-phase-3-trial
#16
Christina H Ruhlmann, Thomas Broe Christensen, Line Hammer Dohn, Merete Paludan, Eva Rønnengart, Ulrich Halekoh, Felix Hilpert, Petra Feyer, Gunnar Kristensen, Olfred Hansen, Dorothy Keefe, Jørn Herrstedt
BACKGROUND: The role of the neurokinin-1 (NK-1) receptor antagonists in the prevention of radiation-induced nausea and vomiting has not been established. The purpose of the GAND-emesis study was to investigate the efficacy and safety of fosaprepitant in combination with palonosetron and dexamethasone in the prevention of nausea and vomiting during 5 weeks of fractionated radiotherapy and concomitant weekly cisplatin in patients with cervical cancer. METHODS: This investigator initiated, multinational, randomised, double-blind, placebo-controlled phase 3 trial, included women with cervical cancer scheduled to receive fractionated radiotherapy and weekly cisplatin 40 mg/m(2) for 5 weeks...
April 2016: Lancet Oncology
https://www.readbyqxmd.com/read/26951840/effect-of-olanzapine-for-breast-cancer-patients-resistant-to-triplet-antiemetic-therapy-with-nausea-due-to-anthracycline-containing-adjuvant-chemotherapy
#17
Junya Sato, Masahiro Kashiwaba, Hideaki Komatsu, Kazushige Ishida, Satoru Nihei, Kenzo Kudo
OBJECTIVE: Triplet antiemetic therapy with neurokinin 1 receptor blocker, 5-hydroxytryptamine receptor blocker and steroids is commonly used in patients who are highly emetic after chemotherapy. However, an alternative antiemetic therapy for patients who are resistant to triplet antiemetic therapy is not established. Olanzapine is recommended in the guidelines as an optional antiemetic drug. However, the effectiveness of adding olanzapine to triplet antiemetic therapy is unknown. In this study, the effectiveness and safety of adding olanzapine to triplet antiemetic therapy with aprepitant, palonosetron and dexamethasone as highly emetic anthracycline-containing adjuvant chemotherapy for primary breast cancer patients were prospectively investigated...
May 2016: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/26870838/new-therapies-for-antiemetic-prophylaxis-for-chemotherapy
#18
Mellar P Davis
A number of new advances have occurred over the past 2 years in the management of chemotherapy-related nausea and vomiting (CINV). A new neurokinin-1 receptor antagonist (NK1RA), netupitant, has been combined with palonosetron in a single oral tablet for treating the effects of moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy (HEC). Rolapitant, another NK1RA, unlike aprepitant, has a long half-life and does not block CYP-3A4 and therefore has fewer drug interactions. Olanzapine reduces nausea more effectively than aprepitant in patients who are receiving HEC and is a better rescue antiemetic than is metoclopramide...
January 2016: Journal of Community and Supportive Oncology
https://www.readbyqxmd.com/read/26694923/state-of-the-art-antiemetic-therapy-for-cancer-patients
#19
Thomas K H Lau, Claudia H W Yip, Winnie Yeo
Nausea and vomiting are common in cancer patients. The most common cause of nausea and vomiting is the administration of cytotoxic chemotherapy. Apart from chemotherapy-induced nausea and vomiting (CINV), biological agents may also cause these symptoms. In this review, discussion will be focused on management of nausea and vomiting due to antineoplastic therapies. The cornerstone of effective management of nausea and vomiting secondary to these antineoplastic drugs is the prevention with the use of appropriate guideline-directed combination antiemetic regimen...
January 2016: Current Oncology Reports
https://www.readbyqxmd.com/read/26629265/akynzeo-netupitant-and-palonosetron-a-dual-acting-oral-agent-approved-by-the-fda-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting
#20
Lisa A Raedler
No abstract text is available yet for this article.
March 2015: American Health & Drug Benefits
keyword
keyword
108375
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"